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Previewspresumably Fz endocytosis and signaling
(Figure 1). Note that PIP2 has a key role in
recruiting and converting AP-2 from the
inactive (closed) to the active (open)
form at the plasma membrane (Jackson
et al., 2010). It has been reported that
Wnt stimulates the production of PIP2
through Fz and Dvl, which activates lipid
kinases PI4K and PIP5K (MacDonald
et al., 2009; Qin et al., 2009). Although
this Fz-Dvl induced PIP2 production has
only been implicated in Wnt/b-catein
signaling thus far, the possibility that it
also accounts for, together with direct
Dvl-binding, AP-2 recruitment to the Fz
complex during PCP signaling deserves
consideration.
Have we arrived at the juncture where
we can explain Dvl specificity in Wnt/
b-catenin and PCP signaling? Unfortu-
nately not. In fact, some recent studies
added more weight to the argument that
the simple notion that the DIX and DEP
domains are specific for Wnt/b-catenin
and PCP signaling, respectively, might
be too simple after all. First, the DEP
domain may have important contributions
to Wnt/b-catenin signaling, for example,
through the aforementioned positivelycharged surface (Simons et al., 2009)
and binding/activating PI4K for PIP and
PIP2 production (Qin et al., 2009). Second,
the DIX domain-mediated Dvl polymeriza-
tion can be regulated by both canonical
and noncanonical Wnt signaling, and
intriguingly by the DEP domain (specifi-
cally the K to M mutation) during nonca-
nonical signaling (Nishita et al., 2010).
Therefore it appears that intramolecular
interactions among different Dvl domains
in Wnt pathways are elaborate and
perhaps regulated, contributing to the
activation of specific downstream events.
The molecular insights on Dvl/AP-2 inter-
action (Yu et al., 2010) help to define
a role of Dvl in PCP signaling, and in addi-
tion, as the authors pointed out, suggest
that the bipartite/combinatory interaction
may be a common theme in cargo/AP-2
coupling.REFERENCES
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The dynamic properties of VDR LBD and full-length VDR/RXRa heterodimer in the presence and absence of
ligands were investigated by hydrogen/deuterium exchange mass spectrometry (Zhang et al., 2010a). The
results beautifully complement X-ray crystal structure data.Nuclear receptors (NRs) exist in a cell inte-
rior and are responsible for sensing the
presence of various molecules, including
steroid and thyroid hormones (Olefsky
and Saltiel, 2000). NRs are one of the
largest classes of drug targets along with
G protein-coupled receptors (GPCRs)
and ion channels. Detailed studies of
NRs are critical not only for understanding
biology but also for the development of
therapeutic agents.Visualization of a protein structure enor-
mously helps our understanding of the
mechanism and function of the protein.
A crystal structure of drug target protein
is the basis of structure-based drug
design. X-ray crystallography is one of
the most powerful driving forces of
modern biology and medicine, though
there are limitations. One limitation is its
applicability. Not all drug targets are crys-
tallizable, let alone all the complexesinvolving drug targets. The other issue is
the static nature of the information
obtained. An X-ray crystal structure of
a protein is a high-resolution snapshot of
a dynamic entity. To fully describe the
protein, it is desirable to obtain the
dynamic characteristics of the protein in
addition to the static structural informa-
tion.
Amide hydrogen/deuterium exchange,
when coupled with proteolysis and mass2010 Elsevier Ltd All rights reserved 1225
Figure 1. General Concept of HDX-MS for Protein-Ligand Interactions
Protein and peptide, green; ligand, orange; deuterium, red. A protein or a protein complex is first incubated in deuterated buffer. After HDX reactions are
quenched by the addition of acid, the deuterated protein is next digested by pepsin. The level of deuterium incorporation in each digested fragment is then deter-
mined by LC-MS (Hamuro et al., 2003). The degree of deuterium incorporation in each peptic fragment can infer dynamic properties of the region of the protein
(Englander and Kallenbach, 1983).
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Previewsspectrometry (HDX-MS) (Figure 1), is
a useful method to complement X-ray
crystallography data (Chandra et al.,
2008). First, HDX-MS is a highly appli-
cable technology and enables scientists
to investigate constructs and complexes
whose structures are not available.
Second, HDX-MS data describe the
dynamic characteristics of a target
protein at the submolecular level (Eng-
lander and Kallenbach, 1983).
HDX-MS is generally a medium-re-
solution, medium-throughput technique
(Hamuro et al., 2003). The resolution is
on average ten amino acids long, depend-
ing on the size of the peptic fragments
generated by the proteolysis. Recent
improvements in automation have
increased the throughput, and one condi-
tion per day is easily accomplished
(for instance, HDX-MS of the apo protein
on one day and HDX-MS of the same
protein with a ligand on the next day).
This methodology recently became appli-
cable to membrane proteins (Hebling
et al., 2010; Zhang et al., 2010b).
In this issue of Structure, Griffin’s group
from Scripps Florida applied HDX-MS to
investigate the dynamic characteristics
of vitamin D receptor (VDR), ligand-
binding domain (LBD), and full-length
VDR/RXRa (retinoid X receptor a) hetero-
dimer (Zhang et al., 2010a) (Figure 2).
In this systematic study, the following
HDX profiles were determined: (1) VDR1226 Structure 18, October 13, 2010 ª2010 ELBD in the absence of ligands; (2) VDR
LBD in the presence of three different
ligands, 1,25D3, ED-71, and alfacalcidol;
(3) full-length VDR/RXRa heterodimer in
the absence of ligands; and (4) full length
VDR/RXRa heterodimer in the presence
of the aforementioned three ligands.
Among eight VDR systems studied,
X-ray crystal structures of two complexes
are available; VDR LBD/1,25D3 (1DB1)
and VDR LBD/ED-71 (2HAR).
The HDX profile of VDR LBD in the
absence of ligands establishes the base-
line for this study (Figure 2A). While the
X-ray crystal structure of apo VDR LBD
is not available, the similarity between
overall HDX pattern of apo VDR LBD and
that of VDR LBD with 1,25D3 suggests
that the overall structure of apo VDR
LBD is similar to that of VDR LBD with
1,25D3. It is important to note that the
HDX profile of apo VDR LBD resembles
those of other apo NR LBDs, such as
PPARg (Hamuro et al., 2006). All of them
have a rigid upper subdomain and a
dynamic lower subdomain containing a
ligand binding pocket.
TheHDXperturbation of VDR LBDupon
binding to each of the three ligands sheds
light on how each ligand interacts with
VDR LBD. While detailed interpretation
of the VDR LBD HDX-MS data is only
possible by comparing with the X-ray
structure data of VDR LBD/1,25D3 and
VDR LBD/ED-71, HDX-MS can probelsevier Ltd All rights reservedthe interactions for which X-ray crystal
structures are not available (e.g., VDR
LBD/alfacalcidol).
The HDX perturbations by 1,25D3 and
ED-71 are very similar, consistent with
their similarly strong transcriptional
potency (Figure 2C). However, a partial
agonist, alfacalcidol, induces a different
HDX perturbation (Figure 2B). The lack
of protection near H11 and H12 is partic-
ularly intriguing and indicates that these
helices remain dynamic when bound to
alfacalcidol. Similar results were obtained
for H11 and H12 of PPARg LBD with full
agonists and a partial agonist (Hamuro
et al., 2006). HDX-MS results support
the idea that the dynamic properties of
H11 and H12 are critical for the transcrip-
tional activity of NRs (Johnson et al., 2000;
Bruning et al., 2007). If this is the case,
HDX-MS can be used as a surrogate
assay to differentiate a full agonist from
a partial agonist. Also the strong protec-
tion (therefore rigidification) near H11
and H12 upon binding to a full agonist
may be the reason why X-ray structures
of NRs with full agonist complexes are
more abundant than those of apo struc-
tures, antagonist complexes, or partial
agonist complexes.
HDX-MS allows one to investigate
physicochemical properties of full-length
VDR/RXRa heterodimer at the submolecu-
lar level (Figure 2D). Crystallization of a ful-
length protein with dynamic regions is
Figure 2. Schematic of Dynamic Properties of VDR LBD in VDR LBD and Full-Length VDR/RXRa Heterodimer
Top row is VDR LBD and bottom row is full-length VDR/RXRa heterodimer. Left column is in the absence of ligand; middle is in the presence of a partial agonist,
alfacalcidol, and right column is in the presence of a full agonist, 1,25D3 or DE-71. Pink is VDR and light blue is RXRa. Gold is a partial agonist and light green is
a full agonist. Blue and dark blue indicate protected regions. Dotted lines indicate an interaction.
(A) The standard state, VDR LBD, in the absence of ligand.
(B) VDR LBD in the presence of a partial agonist, alfacalcidol. A few regions are less dynamic than the standard state (blue).
(C) VDR LBD in the presence of a full agonist, 1,25D3 or DE-71. In addition to the regions protected by the partial agonist (blue), H12 is also protected (blue).
(D) Full-length VDR/RXRa heterodimer in the absence of ligand. A region near H10 that is expected to interact with RXRa exchanges slower than VDR LBD (blue).
(E) Full-length VDR/RXRa heterodimer in the presence of a partial agonist, alfacalcidol. Similar protection as in VDR LBD (blue) was observedwith extra protection
at RXRa interface (dark blue).
(F) Full-length VDR/RXRa heterodimer in the presence of a full agonist, 1,25D3 or DE-71. Similar protection as in VDR LBD (blue) was observed with extra protec-
tion at RXRa interface (dark blue).
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Previewsusually more difficult than that of a rigid
domain, and NRs are no exception.
However, HDX-MS can be applicable to
a full-length protein with dynamic regions
thatmayprevent it fromcrystallizing.Nearly
identical HDX patterns of VDR LBD and
full-length VDR/RXRa heterodimer in the
absence of ligands imply that the structural
integrity of full-length VDR is conserved in
the short construct of VDR LBD.
The resemblance between the HDX
protection of VDR LBD and that of full-
length VDR/RXRa heterodimer upon
binding to the ligands also suggests that
each ligand interacts with VRD LBD and
the heterodimer similarly (Figures 2E and
2F). This observation in a way supports
the validity of rational drug design using
VDR LBD crystal structures.
A natural extension of this study
includes HDX-MS analysis of the RXRamoiety of the heterodimer and HDX-MS
analysis of the effects of various peptide
cofactors on the same complexes
employed here. HDX-MS is a relatively
new and widely applicable technique
that gives unique information on protein
dynamics and complements X-ray struc-
ture data very nicely. Continual growth in
this field is expected.REFERENCES
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